Table 4 Corresponding study data and clinical charcteristics of patients
No. | Age range | Tumor | ECOG PS | No. of prior CHT | Organs involved | Her2 Status1 | Dose level | No. of cycles | Best response |
|---|---|---|---|---|---|---|---|---|---|
01 | 70–80 | Rectum | 1 | 4 | LN, PUL, HEP, ADR | IHC 3+ | 1 | 2 | SD |
02 | 70–80 | Head and neck | 1 | 3 | LN, PUL | IHC 3+ | 1 | 2 | SD |
03 | 40–50 | Rectum | 0 | 3 | LN, SPLEEN, BLADDER, ABDOM WALL | IHC 3+ | 1 | 1 | PD |
04 | 60–70 | Pancreas | 1 | 3 | ABDOM WALL | IHC 2+, ISH + | 5 | 1 | PD |
05 | 50–60 | Breast | 0 | 4 | PUL, OSS, LYMPHANG | IHC 3+ | 5 | 0 | ND |
06 | 50–60 | Breast | 0 | 3 | HEP | IHC 3+ | 5 | 2 | PR |
07 | 50–60 | Rectum | 1 | 3 | LN, PUL, PLEU, ABDOM WALL, PERI | IHC 2+, ISH+ | 5 | 1 | PD |
08 | 40–50 | Stomach | 0 | 4 | LN | IHC 3+ | 9 | 1 | PD |
09 | 50–60 | Breast | 0 | 3 | CHEST WALL, CEREB, HEP, OSS | IHC 3+ | 9 | 1 | PD |
10 | 50–60 | Breast | 0 | 4 | LN, CUT | IHC 3+ | 9 | 1 | PD |
11 | 60–70 | Head and neck | 1 | 4 | PUL, PLEU, OS | IHC 3+ | 13 | 1 | PD |
12 | 50–60 | Stomach | 0 | 4 | PERI, OVAR | IHC 3+ | 13 | 1 | PD |
13 | 30–40 | Breast | 0 | 4 | CUT | IHC 3+ | 13 | 1 | PD |
14 | 50–60 | Stomach | 1 | 1 | LN | IHC 2+ | 13 | 1 | PD |